Facility equipped with 120,000-liter bioreactor capacity

Full operation expected to generate 700 billion won in annual sales, 800 jobs

Campus to reach 360,000-liter total capacity upon completion of three factories

Lotte Biologics holds a completion ceremony for the first factory at its Songdo Bio Campus in Incheon. [Incheon Free Economic Zone Authority]
Lotte Biologics holds a completion ceremony for the first factory at its Songdo Bio Campus in Incheon. [Incheon Free Economic Zone Authority]

A major contract development and manufacturing organization hub has opened in Songdo International City, Incheon, which already accounts for more than 60 percent of South Korea's total pharmaceutical and biotech production output.

The Incheon Free Economic Zone Authority said Wednesday that a completion ceremony was held at Lotte Biologics' Songdo Bio Campus, located within the city's advanced industry cluster.

The ceremony drew a broad gathering of political, business and diplomatic figures, including Incheon Mayor Park Chan-dae, Lotte Group Chairman Shin Dong-bin, Incheon Free Economic Zone Authority chief Kim Jong-cheol, National Assembly members Jeong Il-young, Song Young-gil and Bae Jun-young, Lotte Biologics co-CEOs Shin Yu-yeol and Park James, and Andrew Gately, commercial attaché at the US Embassy in Seoul.

The newly completed first factory is a state-of-the-art production facility equipped with a 120,000-liter bioreactor capacity.

Construction began in March 2024, and the facility was structurally completed in June. Since move-in began in August, more than 750 employees have been based on site, marking the full launch of Lotte Biologics' Songdo operations.

The factory offers end-to-end process capabilities spanning cell line development — the foundation of biopharmaceutical production — small-scale cultivation for clinical material manufacturing, and full-scale finished-product output.

Lotte Biologics said it expects the factory, once fully operational, to generate more than 700 billion won ($523 million) in annual sales and create roughly 800 direct jobs across production, quality control, quality assurance and facilities management.

The company plans to build two additional production factories on its 201,300-square-meter site, bringing total production capacity to 360,000 liters across three facilities, as it accelerates its push into the global CDMO market.

Lotte Biologics also intends to run research and development and commercialization support programs for promising biotech startups, pursuing shared growth with the local biotech ecosystem.

Incheon city said it will use the launch of the large-scale production facility as a springboard to fully implement a two-track strategy that pairs its dominant manufacturing base with expanded research and development capabilities.

Incheon currently concentrates 61.8 percent of South Korea's total pharmaceutical and biotech production — valued at 7.7 trillion won — and 90.3 percent of the country's biotech facility investment.

The city said it will press ahead with plans to establish a K-Bio Lab Hub and an Incheon Institute of Bioscience and Technology, aiming to build a self-contained industrial ecosystem where production, research and development, and talent cultivation reinforce one another.

"The completion of Lotte Biologics' first factory is a valuable achievement showing how bold corporate investment can translate into quality job creation and a leap forward for the local economy," Mayor Park said. "By combining world-class production infrastructure with the research, development and talent-nurturing capabilities Incheon will cultivate, we will secure an unassailable competitive edge for South Korea's biotech industry."


gilbert@heraldcorp.com